The FDA has approved Bracco’s gadopiclenol-based contrast agent, Vueway, for IV MRI imaging in neonates and infants. Vueway is a macrocyclic gadolinium-based contrast agent that delivers effective ...
At this year’s European Congress of Radiology (ECR) in Vienna, Bayer presented new data on a contrast agent that could ...
A new magnetic resonance imaging (MRI) contrast agent being tested by researchers at Case Western Reserve University not only pinpoints breast cancers at early stages but differentiates between ...
A research team from IOCB Prague, working in collaboration with the University of Tübingen, Germany, and the Faculty of Science, Charles University, has developed a new type of contrast agent that can ...
The US Food and Drug Administration (FDA) has granted expanded clearance to Bayer’s Medrad MRXperion, broadening the magnetic resonance (MR) injection system’s application across a wider range of MRI ...
New CT imaging oral contrast agent improves visualization of bowel anatomy, clinical trial data show
ROCHESTER, Minn. — In a new pilot feasibility study, researchers from Mayo Clinic, the University of Washington School of Medicine, the University of California San Francisco, and Nextrast Inc. found ...
A four-question screening checklist administered before echocardiography identified all patients with confirmed polyethylene glycol (PEG) allergy, thereby enabling the selection of non‑PEG ...
The FDA's expanded clearances broaden the application of Bayer's Medrad MRXperion system across a wider range of MR settings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results